DE60036490D1 - Zusammensetzung zur behandlung von prostatakrebs - Google Patents

Zusammensetzung zur behandlung von prostatakrebs

Info

Publication number
DE60036490D1
DE60036490D1 DE60036490T DE60036490T DE60036490D1 DE 60036490 D1 DE60036490 D1 DE 60036490D1 DE 60036490 T DE60036490 T DE 60036490T DE 60036490 T DE60036490 T DE 60036490T DE 60036490 D1 DE60036490 D1 DE 60036490D1
Authority
DE
Germany
Prior art keywords
prostate cancer
composition
treating prostate
living mammal
glycosidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60036490T
Other languages
English (en)
Other versions
DE60036490T2 (de
Inventor
Muharrem Gokcen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunolytics Inc
Original Assignee
Immunolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunolytics Inc filed Critical Immunolytics Inc
Application granted granted Critical
Publication of DE60036490D1 publication Critical patent/DE60036490D1/de
Publication of DE60036490T2 publication Critical patent/DE60036490T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60036490T 1999-10-28 2000-10-25 Zusammensetzung zur behandlung von prostatakrebs Expired - Fee Related DE60036490T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US428375 1999-10-28
US09/428,375 US6428785B1 (en) 1999-10-28 1999-10-28 Method and composition for treating prostate cancer
PCT/US2000/041562 WO2001034176A1 (en) 1999-10-28 2000-10-25 A method and composition for treating prostate cancer

Publications (2)

Publication Number Publication Date
DE60036490D1 true DE60036490D1 (de) 2007-10-31
DE60036490T2 DE60036490T2 (de) 2008-06-19

Family

ID=23698630

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036490T Expired - Fee Related DE60036490T2 (de) 1999-10-28 2000-10-25 Zusammensetzung zur behandlung von prostatakrebs

Country Status (9)

Country Link
US (2) US6428785B1 (de)
EP (1) EP1242110B1 (de)
JP (1) JP2003513931A (de)
CN (1) CN1176714C (de)
AT (1) ATE373483T1 (de)
AU (1) AU2617901A (de)
CA (1) CA2389176A1 (de)
DE (1) DE60036490T2 (de)
WO (1) WO2001034176A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005654B1 (de) * 1997-08-01 2006-04-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur bestimmung von amyloid-ähnlichen fibrillen oder proteinaggregaten
ES2424348T3 (es) * 2002-06-24 2013-10-01 Incept, Llc Cargas y métodos para desplazar tejidos para mejorar los resultados radiológicos
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
WO2005007187A1 (fr) * 2003-07-14 2005-01-27 Viktor Veniaminovich Tets Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l'efficacite du traitement, agents et compositions pharmaceutiques associes
GB2408207A (en) * 2003-11-24 2005-05-25 Johnson & Johnson Medical Ltd Wound dressing for the controlled release of therapeutic agents comprising also an inhibitor of a protease enzyme & a linker group cleavable by such an enzyme
MXPA03011987A (es) * 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
EP1718759A1 (de) * 2004-02-19 2006-11-08 Bayer HealthCare AG Diagnostika und therapeutika für mit kallikrein 3 (klk3) assoziierte krankheiten
WO2005097149A2 (en) * 2004-04-09 2005-10-20 Nicholas Piramal India Limited Herbal extract for renal disorders
JP2008505853A (ja) * 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
KR20070115580A (ko) 2005-03-03 2007-12-06 알러간, 인코포레이티드 클로스트리디움 박테리아를 위한 배지 및 클로스트리디움계독소를 얻기 위한 프로세스
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
WO2007079185A2 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
JP2009543868A (ja) 2006-07-17 2009-12-10 クインテセンス バイオサイエンシーズ インコーポレーティッド 癌治療に関する方法および組成物
US20080027554A1 (en) * 2006-07-31 2008-01-31 Talmadge Karen D Kit and methods of treatment of an intervertebral disc
ES2369547T3 (es) * 2006-11-28 2011-12-01 Cls Therapeutics Limited Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento.
ES2441961T3 (es) 2007-02-15 2014-02-07 Allergan, Inc. Composiciones de toxina botulínica y métodos
CN101313926B (zh) * 2007-05-30 2012-12-26 中央研究院 转录调控物组合物
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
CA2702043A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
MX339068B (es) 2008-08-22 2016-05-10 Anthrogenesis Corp Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
JP2012504423A (ja) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ，インコーポレーテッド 治療用リボヌクレアーゼ
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
EP3583960A1 (de) * 2009-12-15 2019-12-25 Incept, LLC Implantate und biologisch abbaubare bezugsmarkierungen
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN102933221A (zh) 2010-04-08 2013-02-13 人类起源公司 使用胎盘干细胞治疗结节病
WO2012006634A2 (en) * 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
EP2672958A1 (de) 2011-02-08 2013-12-18 Halozyme, Inc. Zusammensetzung und lipidformulierung eines hyaluronan-abbauenden enzym und seine verwendung zur behandlung von benigner prostatahyperplasie
DK2714059T3 (en) 2011-06-01 2019-01-21 Celularity Inc TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
US9943599B2 (en) * 2011-12-22 2018-04-17 Herlev Hospital Therapeutic applications of calcium electroporation to effectively induce tumor necrosis
WO2014026163A2 (en) 2012-08-10 2014-02-13 Osio Corporation d/b/a Yolia Health Contact lens use in the treatment of an ophthalmologic condition
KR20150104092A (ko) 2012-11-15 2015-09-14 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
FI4095130T3 (fi) 2013-10-18 2024-04-25 Novartis Ag Prostataspesifisen membraaniantigeenin (psma) leimattuja estäjiä, niiden käyttö kuvantamisaineina ja farmaseuttisia aineita eturauhassyövän hoitoon
CZ307195B6 (cs) 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů
US10183064B2 (en) * 2014-03-20 2019-01-22 Technion Research & Development Foundation Limited Delivery system comprising a proteolytic enzyme or effector thereof for use in a method for oral treatment and uses thereof
US10064681B2 (en) 2014-04-03 2018-09-04 Corbin Clinical Resources, Llc Method, system, and device for planning and performing, guided and free-handed transperineal prostate biopsies
US10743909B2 (en) * 2014-04-03 2020-08-18 Corbin Clinical Resources, Llc Transperineal prostate biopsy device, systems, and methods of use
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
GB2528304B (en) * 2014-07-17 2020-05-13 Cambridge Univ Hospitals Nhs Foundation Trust Perineal prostate biopsy apparatus
WO2016025922A1 (en) * 2014-08-14 2016-02-18 Dana-Farber Cancer Institute, Inc. Coated particles for drug delivery
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
WO2017074257A1 (en) * 2015-10-26 2017-05-04 Nanyang Technological University Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
CN105255825B (zh) * 2015-11-16 2019-07-19 广州赛莱拉干细胞科技股份有限公司 一种跟腱来源肌腱干细胞原代分离消化液及分离方法
JP2021510539A (ja) 2018-01-16 2021-04-30 シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置
EP3698806A1 (de) * 2019-02-19 2020-08-26 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Chemisches skalpell
CN111705051A (zh) * 2020-07-28 2020-09-25 金紫晶(南京)生物医药技术有限公司 一种复合消化酶及复合消化酶冻干粉
CN112941009B (zh) * 2021-02-22 2024-03-01 新格元(南京)生物科技有限公司 一种ffpe样本预处理液及从ffpe样本中分离单细胞的方法
CN115671267A (zh) * 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4678668A (en) 1985-10-28 1987-07-07 Md Associates Method of reducing soft tissue swelling and pain
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5116615A (en) 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
AU5045690A (en) 1989-01-27 1990-08-24 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
US5051257A (en) 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5958406A (en) * 1994-11-22 1999-09-28 Phairson Medical Inc. Acne treatment with multifunctional enzyme
US5422261A (en) 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
EP0726773A1 (de) 1993-11-17 1996-08-21 Massachusetts Institute Of Technology Verfahren zur hemmung der angiogenese mittels heparinase
EP0766733A4 (de) 1994-06-24 1998-06-10 Boehringer Mannheim Corp Gereinigte mischung aus kollagenase und zwei witeren proteasen aus clostridium histolyticum erhaltend
US5658730A (en) 1994-12-23 1997-08-19 Ctrc Research Foundation Methods of human prostate cancer diagnosis
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
AU7130696A (en) 1995-09-19 1997-04-09 Schering Aktiengesellschaft Combination of beta-interferon for the treatment of prostate cancer
US5783182A (en) 1996-01-30 1998-07-21 Baylor College Of Medicine Method for identifying metastatic sequences
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US5989888A (en) 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
US5716541A (en) 1996-09-23 1998-02-10 Bayer Corporation Azeotrope-like compositions of 1,1,1,3,3 pentafluoropropane and tetramethylsilane
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease

Also Published As

Publication number Publication date
CN1176714C (zh) 2004-11-24
EP1242110A1 (de) 2002-09-25
US20020061300A1 (en) 2002-05-23
WO2001034176A1 (en) 2001-05-17
CA2389176A1 (en) 2001-05-17
US20020106359A1 (en) 2002-08-08
US6428785B1 (en) 2002-08-06
JP2003513931A (ja) 2003-04-15
DE60036490T2 (de) 2008-06-19
US6913744B2 (en) 2005-07-05
ATE373483T1 (de) 2007-10-15
EP1242110B1 (de) 2007-09-19
CN1384754A (zh) 2002-12-11
AU2617901A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
ATE373483T1 (de) Zusammensetzung zur behandlung von prostatakrebs
ATE255418T1 (de) Neurotoxine zur behandlung von pankreatischen krankheiten
MEP26808A (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
ATE409222T1 (de) Verfahren zur herstellung einer reversibel inaktiven, angesäuerten plasminzusammensetzung
IL144032A0 (en) Serine protease inhibitors
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
ATE543509T1 (de) Material und verfahren zur förderung der reparatur von nervengewebe
ATE518540T1 (de) Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
DE60042153D1 (de) Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen
DE60139078D1 (de) Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser-sehkraftkorrektur-chirurgie
ATE121946T1 (de) Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.
ATE255904T1 (de) Fibrin-/fibrinogen-abbau und gerinsel-auflösung durch eine fibrinolytische matrix- metallproteinase
ATE277943T1 (de) Trypsininhibitoren
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE493147T1 (de) Pharmazeutische zusammensetzungen und methoden nützlich zur behandlung von krebs oder leberfibrose
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ES2284528T3 (es) Utilizacion de elastasa para abrir arterias y venas obstruidas.
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
HK1071056A1 (en) Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
EP1060747A3 (de) Fibrin-(fibrinogen-) Abbau und Gerinsel-Auflösung durch eine fibrinolytische Metallproteinase
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE69902999T2 (de) Glucocorticoide zur behandlung von glomerulonephitis
ATE290878T1 (de) Inhibierung von invasiver remodulierung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee